Home Infusion Therapy Market Size, Share, Emerging Trends, Growth Opportunities and Forecast Report 2026–2034
Home Infusion Therapy Market Overview Analysis By Fortune Business Insights Analysis
Market Summary
According to Fortune Business Insights: The global home infusion therapy market was valued at USD 42.44 billion in 2025 and is projected to grow from USD 45.67 billion in 2026 to USD 128.91 billion by 2034, exhibiting a CAGR of 13.85% during the forecast period. Home infusion therapy delivers intravenous and other infused medications to patients in their own homes rather than in hospitals or clinics. Growth is driven by the shift toward home-based care, rising chronic disease prevalence, and the cost advantage of home over hospital infusion. North America led the market with a 41.20% share in 2025.
Key Market Trends
Patients and providers are moving non-critical treatment into home settings, supported by telemedicine, wearables, and remote monitoring tools that make safe at-home administration more practical. Cost is a strong part of this shift: studies cited in the source show home IVIG infusion costing 62% less than administration in a medical office and 87% less than hospital outpatient administration, based on Accredo figures.
Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102989
Key Market Drivers
Chronic disease is a major driver, with roughly 133 million Americans, about 40% of the U.S. population, living with chronic conditions that often require long-term infusion treatment. An aging population adds to demand, as older adults often prefer to receive care at home. Hospital-acquired infections, estimated at about 1.7 million cases per year in the U.S., are pushing patients toward home care, and government programs that shift patients from hospitals to home settings further support growth.
Market Restraints
Limited or absent reimbursement in many developing nations constrains adoption, as does high out-of-pocket spending in countries such as India and China. Shortages of trained personnel and limited provider networks in emerging markets add further barriers. The COVID-era changes to telehealth rules also made some clinical monitoring more difficult for home-based patients.
Market Opportunities
Chemotherapy at home is a growing opportunity, as providers and payers look for ways to move oncology treatment out of hospital settings. Expansion in emerging markets, where the home infusion model is still developing, and continued innovation in infusion devices and telehealth tools also offer room for growth.
Segmentation Analysis
By product, drugs hold the largest share at 77.54% in 2026, while services are expected to grow fastest, followed by devices. By indication, anti-infective therapies lead with a 25.52% share in 2026, while chemotherapy is expected to grow fastest and IVIG (immunoglobulin therapy) is also expected to grow strongly. Hydration, enteral nutrition, and total parenteral nutrition round out the indication categories.
Regional Outlook
North America led the market with a 41.20% share in 2025 (USD 17.49 billion, projected at USD 18.69 billion in 2026), with the U.S. projected at USD 18.19 billion in 2026.
Europe held a 32.26% share (USD 13.69 billion in 2025, USD 14.77 billion projected for 2026), with Germany at USD 3.09 billion and the U.K. at USD 1.92 billion in 2026.
Asia Pacific accounted for a 19.00% share (USD 8.07 billion in 2025, USD 8.81 billion projected for 2026) and is projected to post the highest CAGR, with China at USD 3.02 billion, Japan at USD 1.51 billion, and India at USD 1.34 billion in 2026.
The Rest of the World, described as a nascent market, held a 7.53% share (USD 3.19 billion in 2025, USD 3.40 billion projected for 2026).
Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/102989
Competitive Landscape
Major players include Optum, Option Care Health, Baxter, and B. Braun Melsungen AG, alongside other profiled companies such as CareCentrix, CVS Health, KabaFusion, PromptCare, and Infusystem. Option Care Health's revenue rose 30.1% in 2020 to USD 3,302.6 million.
In January 2024, BrightStar Care and Paragon Healthcare partnered on U.S. home infusion services, and in August 2023, NeuroNet Pro and WeInfuse partnered on neurology infusion workflow tools.
In June 2023, Yale New Haven Health and CarepathRx partnered on home infusion. In March 2021, PromptCare acquired NBN Infusions, a New Jersey provider, and in January 2021, CVS Health and Cancer Treatment Centers of America expanded at-home chemotherapy access, while Eitan Medical opened a U.K. operation.
In February 2020, Avoset launched AvosetGO, a smart infusion pump.
What Everyone Should Know About Japan’s Market Home Infusion Therapy Market Insights
Comments